Gossamer Bio, Inc. (GOSS)
0.1762
+0.02
(+13.90%)
USD |
NASDAQ |
Aug 24, 16:00
0.1699
-0.01
(-3.58%)
After-Hours: 20:00
Gossamer Bio Total Liabilities (Quarterly) : 170.90M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 170.90M |
| March 31, 2026 | 290.38M |
| December 31, 2025 | 295.01M |
| September 30, 2025 | 291.15M |
| June 30, 2025 | 287.03M |
| March 31, 2025 | 286.84M |
| December 31, 2024 | 285.80M |
| September 30, 2024 | 296.74M |
| June 30, 2024 | 291.92M |
| March 31, 2024 | 232.64M |
| December 31, 2023 | 249.15M |
| September 30, 2023 | 243.31M |
| June 30, 2023 | 244.55M |
| March 31, 2023 | 248.36M |
| December 31, 2022 | 260.37M |
| September 30, 2022 | 267.19M |
| June 30, 2022 | 262.30M |
| March 31, 2022 | 264.52M |
| Date | Value |
|---|---|
| December 31, 2021 | 222.19M |
| September 30, 2021 | 217.23M |
| June 30, 2021 | 211.82M |
| March 31, 2021 | 210.38M |
| December 31, 2020 | 218.75M |
| September 30, 2020 | 212.08M |
| June 30, 2020 | 204.75M |
| March 31, 2020 | 65.02M |
| December 31, 2019 | 74.12M |
| September 30, 2019 | 70.88M |
| June 30, 2019 | 65.73M |
| March 31, 2019 | 35.69M |
| December 31, 2018 | 21.12M |
| September 30, 2018 | 15.59M |
| June 30, 2018 | |
| March 31, 2018 | |
| December 31, 2017 | 7.307M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| United Therapeutics Corp. | 819.80M |
| Arbutus Biopharma Corp. | 15.29M |
| Kura Oncology, Inc. | 539.36M |
| ACADIA Pharmaceuticals, Inc. | 436.29M |
| Alnylam Pharmaceuticals, Inc. | 4.205B |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 76.87M |
| Shareholders Equity (Quarterly) | -94.03M |
| Debt to Equity Ratio | -0.4261 |
| Current Ratio | 0.5278 |
| Net Debt Paydown Yield | 40.45% |